Design of Potent and Selective Agonists for the Human Vasopressin V 1b Receptor Based on Modifications of [Deamino-Cys 1]arginine Vasopressin at Position 4

Journal of Medicinal Chemistry

Volumn 47, Issue 9, 2004, Pages 2375-2388

  Cheng, Ling Ling ^b   Stoev, Stoytcho ^b   Manning, Maurice ^b   Derick, Sylvain ^a   Pena, Ana ^a   Mimoun, Mohamed Ben ^a   Guillon, Gilles ^a  

^a INSERM   (France)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; AMINO ACID; ARGIPRESSIN DERIVATIVE; ARGIPRESSIN[1 DEAMINO 4 CYCLOHEXYLALANINE]; ARGIPRESSIN[1 DEAMINOCYSTEINE]; ARGIPRESSIN[4 ALANINE]; ARGIPRESSIN[4 ARGININE]; ARGIPRESSIN[4 ASPARAGINE]; ARGIPRESSIN[4 GLUTAMINE]; ARGIPRESSIN[4 GLYCINE]; ARGIPRESSIN[4 ISOLEUCINE]; ARGIPRESSIN[4 LEUCINE]; ARGIPRESSIN[4 LYSINE]; ARGIPRESSIN[4 NORVALINE]; ARGIPRESSIN[4 ORNITHINE]; ARGIPRESSIN[4 PHENYLALANINE]; ARGIPRESSIN[4 SERINE]; ARGIPRESSIN[4 THIENYLALANINE]; ARGIPRESSIN[4 THREONINE]; ARGIPRESSIN[4 TRYPTOPHAN]; ARGIPRESSIN[4 TYROSINE]; DESMOPRESSIN; GLUTAMINE; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; OXYTOCIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL; CONTROLLED STUDY; DEAMINATION; DRUG RECEPTOR BINDING; NONHUMAN; PEPTIDE SYNTHESIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; RECEPTOR AFFINITY; RECEPTOR BINDING;

ANIMALS; CHO CELLS; CRICETINAE; CYCLIC AMP; DEAMINO ARGININE VASOPRESSIN; HUMANS; INOSITOL PHOSPHATES; PEPTIDES, CYCLIC; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1842628615     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030611c     Document Type: Article

References (83)

1. du Vigneaud, V.; Gish., D. T.; Katsoyannis, P. G. A synthetic preparation possessing biological properties associated with arginine-vasopressin. J. Am. Chem. Soc. 1954, 76, 4751-4752.
2. Jard, S. Vasopressin receptors. A historical survey. In Advances in Experimental Medicine and Biology; Zingg, H. H., Bourque, C. W., Bichet, D. G., Eds.; Plenum Press: New York, 1998; pp 1-13.
3. Barberis, C.; Mouillac, B.; Durroux, T. Structural bases of vasopressin/oxytocin receptor function. J. Endocrinol. 1998, 156, 223-229.
4. Barberis, C.; Morin, D.; Durroux, T.; Mouillac, B.; Guillon, G.; Seyer, R.; Hibert, M.; Tribollet, E.; Manning, M. Molecular pharmacology of AVP and OT receptors and therapeutic potential. Drug News Perspect. 1999, 12, 279-292.
5. Antoni, F. A. Novel ligand specificity of pituitary vasopressin receptors in the rat. Neuroendocrinology 1984, 39, 186-188.
6. Jard, S.; Gaillard, R. C.; Guillon, G.; Marie, J.; Schoenenberg, P.; Muller, A. F.; Manning, M.; Sawyer, W. H. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. Mol. Pharmacol. 1986, 30, 171-177.
7. Griebel, G.; Simiand, J.; Serradeil-Le Gal, C.; Wagnon, J.; Pascal, M.; Scatton, B.; Maffrand, J. P.; Soubrie, P. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 6370-6375.
8. Grazzini, E.; Lodboerer, A. M.; Perez-Martin, A.; Joubert, D.; Guillon, G. Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla. Endocrinology 1996, 137, 3906-3914.
9. (a) Lee, B.; Yang, C.; Chen, T. H.; al-Azawi, N.; Hsu, W. H. Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. Am. J. Physiol.: Endocrinol. Metab. 1995, 269, E1095-E1100.
10. (b) Yibchok-Anun, S.; Cheng, H.; Heine, P. A.; Hsu, W. H. Characterization of receptors mediating AVP- and OT-induced glucagon release from the rat pancreas. Am. J. Physiol. Endocrinol. Metab. 1999, 277, E56-E62.
11. 1b receptors: characterization in In-R1-G9 cells and localization in human pancreas. Am. J. Physiol. Endocrinol. Metab. 2003, 285, E566-E576.
12. Kimura, T.; Tanizawa, O.; Mori, K.; Brownstein, M. J.; Okayama, H. Structure and expression of a human oxytocin receptor. Nature 1992, 356, 526-529.
13. Morel, A.; O'Carroll, A. M.; Brownstein, M. J.; Lolait, S. J. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 1992, 356, 523-526.
14. Birnbaumer, M.; Seibold, A.; Gilbert, S.; Ishido, M.; Barberis, C.; Antaramian, A.; Brabet, T.; Rosenthal, W. Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992, 357, 333-335.
15. Lolait, S. J.; O'Carroll, A. M.; McBride, O. W.; Konig, M.; Morel, A.; Brownstein, M. J. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992, 357, 336-339.
16. Gorbulev, V.; Buchner, H.; Akhundova, A.; Fahrenholz, F. Molecular cloning and functional characterization of V2 [8-lysine] vasopressin and oxytocin receptors from a pig kidney cell line. Eur. J. Biochem. 1993, 215, 1-7.
17. Thibonnier, M.; Auzan, C.; Madhun, Z.; Wilkins, P.; Berti-Mattera, L.; Clauser, E. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J. Biol. Chem. 1994, 269, 3304-3310.
18. Sugimoto, T.; Saito, M.; Mochizuki, S.; Watanabe, Y.; Hashimoto, S.; Kawashima, H. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J. Biol. Chem. 1994, 269, 27088-27092.
19. de Keyzer, Y.; Auzan, C.; Lenne, F.; Beldjord, C.; Thibonnier, M.; Bertagna, X.; Clauser, E. Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett. 1994, 356, 215-220.
20. Mouillac, B.; Chini, B.; Balestre, M. N.; Elands, J.; Trumpp-Kallmeyer, S.; Hoflack, J.; Hibert, M.; Jard, S.; Barberis, C. The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. J. Biol. Chem. 1995, 270, 25771-25777.
21. Chini, B.; Mouillac, B.; Ala, Y.; Balestre, M. N.; Trumpp-Kallmeyer, S.; Hoflack, J.; Elands, J.; Hibert, M.; Manning, M.; Jard, S.; Barberis, C. Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. EMBO J. 1995, 14, 2176-2182.
22. Cotte, N.; Balestre, M. N.; Phalipou, S.; Hibert, M.; Manning, M.; Barberis, C.; Mouillac, B. Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor. J. Biol. Chem. 1998, 273, 29462-29468.
23. (a) Cotte, N.; Balestre, M. N.; Aumelas, A.; Mahe, E.; Phalipou, S.; Morin, D.; Hibert, M.; Manning, M.; Durroux, T.; Barberis, C.; Mouillac, B. Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding. Eur. J. Biochem. 2000, 267, 4253-4263.
24. 1a vasopressin receptor is part of the conformational switch controlling activation by agonist. Eur. J. Biochem. 2003, 270, 4681-4688.
25. Sawyer, W. H.; Manning, M. Experimental uses of neurohypophysial hormone analogs. Trends Endocrinol. Metab. 1989, 1, 48-50.
26. Manning, M.; Sawyer, W. H. Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J. Recept. Res. 1993, 13, 195-214.
27. Loichot, C.; Grima, M.; De Jong, W.; Helwig, J. J.; Imbs, J. L.; Barthelmebs, M. Oxytocin-induced renin secretion by denervated kidney in anaesthetized rat. Eur. J. Pharmacol. 2002, 454, 241-247.
28. Tsuchiya, M.; Tsuchiya, K.; Maruyama, R.; Takemura, G.; Minatoguchi, S.; Fujiwara, H. Vasopressin inhibits sarcolemmal ATP-sensitive K+ channels via V1 receptors activation in the guinea pig heart. Circ. J. 2002, 66, 277-282.
29. Goodson, J. L.; Bass, A. H. Forebrain peptides modulate sexually polymorphic vocal circuitry. Nature 2000, 403, 769-772.
30. Monteagudo, P. T.; Gavras, H.; Gavras, I.; Kohlmann, O., Jr.; Ribeiro, A. B.; Zanella, M. T. Role of vasopressin in 24-hour blood pressure regulation in diabetic patients with autonomic neuropathy. Am. J. Hypertens. 2002, 15, 42-47.
31. Pettibone, D. J.; Freidinger, R. M. Discovery and development of non-peptide antagonists of peptide hormone receptors. Biochem. Soc. Trans. 1997, 25, 1051-1057.
32. Chan, W. Y.; Wo, N. C.; Stoev, S.; Cheng, L. L.; Manning, M. Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays. Exp. Physiol. 2000, 85, 7S-18S.
33. Verbalis, J. G. Vasopressin V2 receptor antagonists. J. Mol. Endocrinol. 2002, 29, 1-9.
34. Serradeil-Le Gal, C. An overview of SR121463, a selective nonpeptide vasopressin V(2) receptor antagonist. Cardiovasc. Drug Rev. 2001, 19, 201-214.
35. Thibonnier, M.; Coles, P.; Thibonnier, A.; Shoham, M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu. Rev. Pharmacol. Toxicol. 2901, 41, 175-202.
36. Serradeil-Le Gal, C.; Wagnon, J.; Valette, G.; Garcia, G.; Pascal, M.; Maffrand, J. P.; Le Fur, G. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog. Brain Res. 2002, 139, 197-210.
37. Bloom, D. A. The American experience with desmopressin. Clin. Pediatr. 1993, 28-31.
38. Mannucci, P. M. Treatment of von Willebrand disease. Int. J. Clin. Lab. Res. 1998, 28, 211-224.
39. Husslein, P. Development and clinical experience with the new evidence-based tocolytic atosiban. Acta Obstet. Gynecol. Scand. 2002, 81, 633-641.
40. Vatish, M.; Thornton, S. Oxytocin antagonists (Expert Opinion). Expert Opin. Ther. Pat. 2002, 12, 1403-1406.
41. (a) Sawyer, W. H. Biologic assays for oxytocin and vasopressin. Methods Med. Res. 1961, 9, 210-219.
42. (b) Sturmer, E. Vasopressin, oxytocin and synthetic analogues: the use of bioassays. J. Pharm. Biomed. Anal. 1989, 7, 199-210.
43. Serradeil-Le Gal, C.; Wagnon, J.; Simiand, J.; Griebel, G.; Lacour, C.; Guillon, G.; Barberis, C.; Brossard, G.; Soubrie, P.; Nisato, D.; Pascal, M.; Pruss, R.; Scatton, B.; Maffrand, J. P.; Le Fur, G. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl) -2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J. Pharmacol. Exp. Ther. 2002, 300, 1122-1130.
44. 1b-receptor in mammals. Stress 2003, 6, 199-206.
45. Derick, S.; Cheng, L. L.; Voirol, M. J.; Stoev, S.; Giacomini, M.; Wo, N. C.; Szeto, H. H.; Ben Mimoun, M.; Andres, M.; Gaillard, R. C.; Guillon, G.; Manning, M. [1-Deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology 2002, 143, 4655-4664.
46. 8]-vasopressin, two analogues possessing an antidiuretic activity more elevated and selective than that of the natural vasopressins). Helv. Chim. Acta 1966, 49, 695-705.
47. Sawyer, W. H.; Acosta, M.; Balaspiri, L.; Judd, J.; Manning, M. Structural changes in the arginine vasopressin molecule that enhance antidiuretic activity and specificity. Endocrinology 1974, 94, 1106-1115.
48. Manning, M.; Coy, E. J.; Acosta, M.; Sawyer, W. H. Solid-phase synthesis and some pharmacological properties of deamino-4-threonine analogs of the vasopressins and vasotocin and [deamino]arginine-vasotocin. J. Med. Chem. 1973, 16, 836-839.
49. Gillessen, D.; du Vigneaud, V. Synthesis and pharmacological properties of 4-decarboxamide-8-arginine-vasopressin and its 1-deamino analog. J. Med. Chem. 1970, 13, 346-349.
50. 4]arginine-vasopressin and two related analogues. Acta Chem. Scand. 1985, B39, 453-457.
51. 1b receptor. In Peptides; Benedetti, E., Pedone, C., Eds.; Edizioni Ziino: Napoli, Italy, 2002; pp 554-555.
52. Merrifield, B. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 1963, 85, 2149-2154.
53. Merrifield, B. Solid phase synthesis. Science 1986, 232, 341-347.
54. Stewart, J. M.; Young, J. D. Solid Phase Synthesis; Pierce Chemical Company: Rockford, IL, 1984.
55. Atherton, E.; Sheppard, R. C. Reaction procedures and operating techniques (Chapter 10) and resin cleavage and purification (Chapter 11). Solid-Phase Synthesis: A Practical Approach; IRL Press: Oxford, New york, Tokyo, 1989; pp 131-161.
56. Rink, H. Solid-phase synthesis of protected fragments using a trialkoxydiphenyl-methylester resin. Tetrahedron Lett. 1987, 28, 3787-3790.
57. Fields, G. B.; Noble, R. L. Solid phase synthesis utilizing 9-fluorenylmethoxycarbonyl amino acid. Int. J. Pept. Protein Res. 1990, 35, 161-214.
58. Manning, M. Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin. J. Am. Chem. Soc. 1968, 90, 1348-1349.
59. Manning, M.; Coy, E.; Sawyer, W. H. Solid-phase synthesis of [4-threonine]-oxytocin. A more potent and specific oxytocic agent than oxytocin. Biochemistry 1970, 9, 3925-3930.
60. Manning, M.; Coy, E. J.; Sawyer, W. H.; Acosta, M. Solid-phase synthesis and some pharmacological properties of 4-threonine analogs of vasopressins and vasotocin and of arginine-vasopressin and arginine-vasotocin. J. Med. Chem. 1973, 16, 463-466.
61. Konig, W.; Geiger, R. New method for synthesis of peptides: activation of the carboxyl group with dicyclohexylcarbodiimide using 1-hydroxybenzotriazoles as additives. Chem. Ber. 1970, 103, 788-798.
62. Bodanszsky, M.; du Vigneaud, V. A method of synthesis of long peptide chains using a synthesis of oxytocin as an example. J. Am. Chem. Soc. 1959, 81, 5688-5691.
63. Bodanszsky, M.; Sheehan, J. T. Active esters and resins in peptide synthesis. Chem. Ind. 1964, 1423-1424.
64. du Vigneaud, V.; Ressler, C.; Swan, J. M.; Roberts, C. W.; Katsoyannis, P. G. The synthesis of oxytocin. J. Am. Chem. Soc. 1954, 76, 3115-3121.
65. Bodanszsky, M.; Bodanszsky, A.; Chandramouli, N.; Kwei, J. Z.; Martinez, J.; Tolle, J. C. Active esters of 9-fluorenylmethyloxycarbonyl amino acid and their application in the stepwise lengthening of peptide chain. J. Org. Chem. 1980, 45, 72-76.
66. Rivier, J.; Keiser, R.; Galyean, R. Solid phase synthesis of somatostatin and glucagon-selective analogs in gram quantities. Biopolymers 1978, 17, 1927-1938.
67. Manning, M.; Wuu, T. C.; Baxter, J. W. M. The purification of synthetic oxytocin and analogues by gel filtration on Sephadex G-15. J. Chromatogr. 1968, 38, 396-398.
68. Schwartz, J.; Derdowska, I.; Sobocinska, M.; Kupryszewski, G. A potent new synthetic analog of vasopressin with relative agonist specificity for the pituitary. Endocrinology 1991, 129, 1107-1109.
69. Zaoral, M.; Kolc, J.; Sorm, F. Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-γ-aminobutyrine-vasopressin, 1-deamino-8-D-lysine-vasopressin and 1-deamino-8-D-arginine-vasopressin. Collect. Czech. Chem. Commun. 1967, 32, 1250-1257.
70. (a) Tahara, A.; Saito, M.; Sugimoto, T.; Tomura, Y.; Wada, K.; Kusayama, T.; Tsukada, J.; Ishii, N.; Yatsu, T.; Uchida, W.; Tanaka, A. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 1998, 125, 1463-1470.
71. 1b vasopressin receptor. Biochem. Pharmacol. 1997, 53, 1711-1717.
72. 1a receptors reveal surprising species differences. In Peptides 2000; Martinez, J., Fehrentz, J. A., Eds.; EDK, Editions Medicales et Scientifiques: Paris, 2001; pp 589-590.
73. Chini, B.; Mouillac, B.; Balestre, M. N.; Trumpp-Kallmeyer, S.; Hoflack, J.; Hibert, M.; Andriolo, M.; Pupier, S.; Jard, S.; Barberis, C. Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. FEBS Lett. 1996, 397, 201-206.
74. 1 receptor of rat, rhesus and human tissues. Life Sci. 1992, 50, 1953-1958.
75. 1)conotoxin GI analogs in the mouse diaphragm. Int. J. Pept. Protein Res. 1989, 34, 455-462.
76. Al-Obeidi, F.; Sanderson, D. G.; Hruby, V. J. Synthesis of beta- and gamma-fluorenylmethyl esters of respectively N-alpha-Boc-L-aspartic acid and N-alpha-Boc-L-glutamic acid. Int. J. Pept. Protein Res. 1990, 35, 215-218.
77. Felix, A. M.; Fournier, A.; Wang, C. T.; Heimer, E. P.; Fournier, A.; Applications of BOP reagent in solid phase synthesis. II. Solid phase side-chain to side-chain cyclizations using BOP reagent. Int. J. Pept. Protein Res. 1988, 31, 231-238.
78. Phalipou, S.; Cotte, N.; Carnazzi, E.; Seyer, R.; Mahe, E.; Jard, S.; Barberis, C.; Mouillac, B. Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J. Biol. Chem. 1997, 272, 26536-26544.
79. Andres, M.; Trueba, M.; Guillon, G. Pharmacological characterization of F-180: a selective human V(1a) vasopressin receptor agonist of high affinity. Br. J. Pharmacol. 2002, 135, 1828-1836.
80. 9] OVT: a selective oxytocin receptor ligand. Eur. J. Pharmacol. 1988, 147, 197-207.
81. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
82. Guillon, G.; Trueba, M.; Joubert, D.; Grazzini, E.; Chouinard, L.; Cote, M.; Payet, M. D.; Manzoni, O.; Barberis, C.; Robert, M.; Gallot-Payet, N. Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. Endocrinology 1995, 136, 1285-1295.
83. Salomon, Y.; Londos, C.; Rodbell, M. A highly sensitive adenylate cyclase assay. Anal. Biochem. 1974, 58, 541-548.